Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 4.15
(-14.43%)
USD 4.15
(-14.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 48.44 Million USD | -28.6% |
| 2022 | 67.84 Million USD | -44.67% |
| 2021 | 122.62 Million USD | 0.83% |
| 2020 | 121.61 Million USD | -2.42% |
| 2019 | 124.63 Million USD | 7.46% |
| 2018 | 115.97 Million USD | 338.42% |
| 2017 | 26.45 Million USD | -80.27% |
| 2016 | 134.09 Million USD | 105.94% |
| 2015 | 65.11 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 47.88 Million USD | 3.27% |
| 2024 Q1 | 46.37 Million USD | -4.28% |
| 2023 Q4 | 48.44 Million USD | -2.91% |
| 2023 FY | 48.44 Million USD | -28.6% |
| 2023 Q3 | 49.89 Million USD | 1.81% |
| 2023 Q1 | 48.76 Million USD | -28.12% |
| 2023 Q2 | 49 Million USD | 0.5% |
| 2022 Q2 | 116.53 Million USD | -0.28% |
| 2022 Q4 | 67.84 Million USD | -21.72% |
| 2022 Q3 | 86.66 Million USD | -25.63% |
| 2022 FY | 67.84 Million USD | -44.67% |
| 2022 Q1 | 116.85 Million USD | -4.7% |
| 2021 Q4 | 122.62 Million USD | -7.35% |
| 2021 Q2 | 131.19 Million USD | 9.3% |
| 2021 FY | 122.62 Million USD | 0.83% |
| 2021 Q3 | 132.34 Million USD | 0.88% |
| 2021 Q1 | 120.03 Million USD | -1.3% |
| 2020 Q3 | 119.06 Million USD | 2.14% |
| 2020 Q2 | 116.56 Million USD | -0.38% |
| 2020 Q1 | 117.01 Million USD | -6.11% |
| 2020 FY | 121.61 Million USD | -2.42% |
| 2020 Q4 | 121.61 Million USD | 2.14% |
| 2019 Q4 | 124.63 Million USD | 5.66% |
| 2019 Q2 | 117.74 Million USD | 2.7% |
| 2019 Q1 | 114.64 Million USD | -1.15% |
| 2019 FY | 124.63 Million USD | 7.46% |
| 2019 Q3 | 117.95 Million USD | 0.18% |
| 2018 FY | 115.97 Million USD | 338.42% |
| 2018 Q4 | 115.97 Million USD | 297.99% |
| 2018 Q1 | 24.71 Million USD | -6.56% |
| 2018 Q2 | 27.49 Million USD | 11.24% |
| 2018 Q3 | 29.14 Million USD | 5.98% |
| 2017 FY | 26.45 Million USD | -80.27% |
| 2017 Q4 | 26.45 Million USD | 6.55% |
| 2017 Q3 | 24.82 Million USD | -81.75% |
| 2017 Q2 | 136.01 Million USD | 798.29% |
| 2017 Q1 | 15.14 Million USD | -88.71% |
| 2016 Q4 | 134.09 Million USD | 0.0% |
| 2016 FY | 134.09 Million USD | 105.94% |
| 2015 FY | 65.11 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 92.237% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 61.582% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 92.157% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 81.701% |
| bluebird bio, Inc. | 424.62 Million USD | 88.591% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 29.544% |
| Imunon, Inc. | 8.53 Million USD | -467.908% |
| Editas Medicine, Inc. | 150.05 Million USD | 67.715% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.764% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.618% |
| Myriad Genetics, Inc. | 312.9 Million USD | 84.517% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 95.248% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 90.062% |
| Verastem, Inc. | 71.18 Million USD | 31.945% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.93% |
| Waters Corporation | 3.47 Billion USD | 98.607% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.907% |
| Biogen Inc. | 12.04 Billion USD | 99.598% |
| Nektar Therapeutics | 267.04 Million USD | 81.859% |
| Perrigo Company plc | 6.04 Billion USD | 99.198% |
| Dynavax Technologies Corporation | 375.02 Million USD | 87.082% |
| Illumina, Inc. | 4.36 Billion USD | 98.89% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -37.717% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 75.25% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 81.112% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -29.907% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.437% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 41.231% |
| Evolus, Inc. | 209.68 Million USD | 76.897% |
| Adicet Bio, Inc. | 37.12 Million USD | -30.509% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -20.432% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.318% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 92.669% |
| FibroGen, Inc. | 585.72 Million USD | 91.729% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.015% |
| OPKO Health, Inc. | 622.47 Million USD | 92.217% |
| Homology Medicines, Inc. | 118.53 Million USD | 59.13% |
| Geron Corporation | 146.12 Million USD | 66.847% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 98.804% |
| Exelixis, Inc. | 678.44 Million USD | 92.859% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -141.368% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -286.509% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 80.684% |
| Zoetis Inc. | 9.29 Billion USD | 99.479% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 87.805% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 1.486% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.059% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.139% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 97.986% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 57.805% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.063% |
| Blueprint Medicines Corporation | 918.64 Million USD | 94.726% |
| Insmed Incorporated | 1.66 Billion USD | 97.085% |
| TG Therapeutics, Inc. | 169.08 Million USD | 71.349% |
| Incyte Corporation | 1.59 Billion USD | 96.957% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 95.914% |